Safety and efficacy of Hydroxychloroquine and Chloroquine in treatment of COVID-19: A rapid review of evidence
Abstract
Context: The coronavirus (named COVID-19) 2019 pandemic has caused significant morbidity and mortality around the world and has created serious challenges for health systems. To date, no medical treatment is developed for COVID-19 with proven effectiveness. This study is a rapid review aimed to identify and summarize evidence on the efficacy and safety of Hydroxychloroquine (HCQ) and Chloroquine (CQ) for COVID-19 infection.
Methods: This study is a rapid review that systematically searched electronic databases, including PubMed, EMBASE, ClinicalTrials.gov, and Cochrane Library, until May 22, 2020. Peer-reviewed randomized clinical trials, reviews, and observational studies on the efficacy and safety of HCQ and CQ for the prevention and treatment of COVID-19 infection were included.
Results: There were seven review articles, five clinical trial studies, and eight observational studies focusing on CQ or HCQ to treat COVID-19 patients. Of five clinical trials, three reported favorable outcomes among patients who received CQ or HCQ. Of eight observational studies, four reported no difference between the use of HCQ alone or combined administration of HCQ and Azithromycin with other medications. Three studies showed that the combined administration of HCQ and Azithromycin or HCQ alone is associated with improved clinical outcomes.
Conclusions: The included studies reported conflicting results on the efficacy and safety of HCQ and CQ in treating COVID-19. Therefore, it seems that there is not sufficient evidence about the effectiveness and safety of HCQ and CQ to treat patients with COVID-19 and more studies, which also report long-term follow up results, are needed..
2. Taccone FS, Gorham J, Vincent J-L. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. The Lancet Respiratory Medicine. 2020.
3. Pereira BB. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. Journal of Toxicology and Environmental Health, Part B. 2020:1-5.
4. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care. 2020.
5. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020;30(3):269-71.
6. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020.
7. Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020:105949.
8. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020.
9. Pacheco RL, Riera R. Hydroxychloroquine and chloroquine for COVID-19 infection. Rapid systematic review. Journal of EvidenceBased Healthcare. 2020;2(1).
10. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with Chloroquine. Journal of Molecular Cell Biology. 2020;12(4):322-5. doi:10.1093/jmcb/mjaa014.
11. 11. Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP open. 2020.
12. Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, et al. Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases. Oxford University Press US; 2020. p. ofaa130.
13. Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19). International Journal of Rheumatic Diseases. 2020.
14. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Network Open. 2020;3(4):e208857-e. doi:10.1001/jamanetworkopen.2020.8857.
15. Chowdhury MS, Rathod J, Gernsheimer J. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. Academic Emergency Medicine. 2020;27(6):493-504. doi:10.1111/acem.14005.
16. Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020.
doi:10.1016/j.hrthm.2020.05.014. [PubMed:32407884]. [PubMed Central:PMCPMC7214283].
17. Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease. 2020;35:101738. doi:10.1016/j.tmaid.2020.101738.
18. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, etal. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine.2020;382(25):2411-8. doi:10.1056/NEJMoa2012410.
19. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020;323(24):2493-502.doi:10.1001/jama.2020.8630.
20. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.doi:10.1136/bmj.m1844.
21. Yu B, Li C, Chen P, Zhou N, Wang L, Li J, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020:1-7. doi:10.1007/s11427-020-1732-2. [PubMed:32418114]. [PubMed Central:PMCPMC7228868 any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.].
22. Gautret P, Lagier J-C, Parola P, Meddeb L, Sevestre J, Mailhe M, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Medicine and Infectious Disease. 2020:101663.
23. Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020:30085-8.
24. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020.
25. Chen J, LIU D, LIU L, LIU P, XU Q, XIA L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University (Medical Science). 2020;49(1):0-.
| Files | ||
| Issue | Vol 4, No 1 (2020) | |
| Section | Review Article | |
| DOI | https://doi.org/10.18502/htaa.v4i1.5864 | |
| Keywords | ||
| Hydroxychloroquine; Chloroquine; COVID-19; Safety; Efficacy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
